ES2353437T3 - Derivados de pirrolidina como inhibidores de erk. - Google Patents
Derivados de pirrolidina como inhibidores de erk. Download PDFInfo
- Publication number
- ES2353437T3 ES2353437T3 ES07750497T ES07750497T ES2353437T3 ES 2353437 T3 ES2353437 T3 ES 2353437T3 ES 07750497 T ES07750497 T ES 07750497T ES 07750497 T ES07750497 T ES 07750497T ES 2353437 T3 ES2353437 T3 ES 2353437T3
- Authority
- ES
- Spain
- Prior art keywords
- substituted
- alkyl
- group
- independently selected
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un compuesto de formula 1.0: **Fórmula** o sus sales farmaceuticamente aceptables, donde: Y1, Y2, y Y3 se seleccionan cada uno independientemente del grupo que consiste en: -CH= y -CR9=; z es 1; Q es un sustituyente seleccionado del grupo que consiste en: **Fórmula** Cada Q1 representa un anillo seleccionado independientemente del grupo que consiste en: cicloalquilo, cicloalquilo sustituido, heterocicloalquilo, heterocicloalquilo sustituido, arilo, arilo sustituido, heteroarilo, y heteroarilo sustituido, donde dichos anillos sustituidos estan sustituidos con 1 a 3 sustituyentes seleccionados independientemente del grupo que consiste en: los radicales R10; siempre que cuando Q1 es arilo, heteroarilo, arilo sustituido o heteroarilo sustituido los atomos de carbono en la union del anillo no estan sustituidos; Q2 representa un anillo seleccionado del grupo que consiste en: cicloalquilo, cicloalquilo sustituido, heterocicloalquilo, y heterocicloalquilo sustituido, donde dichos anillos sustituidos estan sustituidos con 1 a 3 sustituyentes seleccionados independientemente del grupo que consiste en: los radicales R10; Z1 representa -(C(R24)2)w- donde cada R24 se selecciona independientemente del grupo que consiste en: H, alquilo y F, y donde w es 1, 2 o 3, y generalmente w es 1 o 2, y usualmente w es 1, y donde en un ejemplo cada R24 es H, y en otro ejemplo w es 1, y en otro ejemplo cada R24 es H y w es 1, preferiblemente w es 1 y cada R24 es H; Z2 se selecciona del grupo que consiste en: -N(R44)-, -O- y -C(R46)2-; m es de 1 a 6; n es de 1 a 6; p es de 0 a 6; t es 0, 1, o 2; R1 se selecciona del grupo que consiste en: (1) -CN, (2) -NO2, (3) -OR10, (4) -SR10, (5) -N(R10)2, (6) R10, (7) halo, (8) -CF3; (9) alquenilo; (10) -C(O)N(R10)2 donde cada R10 se selecciona independientemente, y preferiblemente cada R10 se selecciona independientemente del grupo que consiste en: (a) H, (b) alquilo, (c) heteroarilo, (d) arilo, y (e) cicloalquilo, donde por ejemplo, cada R10 se selecciona del grupo que consiste en: H, metilo, butilo, i-propilo, piridilo, fenilo y ciclopropilo, donde, por ejemplo, dicho -C(O)N(R10)2 radical se selecciona del grupo que consiste en: -C(O)NH2, -C(O)NH(CH3), -C(O)NH(CH)(CH3)2, -C(O)NH(C4H9), -C(O)NH(C6H5), -C(O)NH(C3H5), y -C(O)NH(C5H4N); (11) arilalquenilo-; R2 se selecciona del grupo que consiste en: (1) H, (2) -CN, (3) halo, (4) alquilo, (5) alquilo sustituido donde dicho alquilo sustituido esta sustituido con 1 a 3 sustituyentes seleccionados del grupo que consiste en: (a) -OH, (b) -O-alquilo (p. ej., -O-(alquilo C1-C3), (c) -Oalquilo (p. ej., -O-(alquilo C1-C3)) sustituido con 1 a 3 atomos de F, y (d) -N(R40)2 donde cada R40 se selecciona independientemente del grupo que consiste en: (i) H, (ii) alquilo C1-C3 y (iii) -CF3, (6) alquinilo, (7) alquenilo, (8) -(CH2)mR11, (9) -N(R26)2, (10) -OR23, (11) -N(R26)C(O)R42, (12) cicloalquilo, (13) cicloalquilalquilo, y (14) **Fórmula** cada R3, R4, R5, R6 y R7 se selecciona independientemente del grupo que consiste en: (1) H, (2) alquenilo, (3) alquenilo sustituido, (4) alquilo, (5) alquilo sustituido, (6) cicloalquilo, (7) cicloalquilo sustituido, (8) cicloalquilalquilo-, (9) cicloalquilalquilo- sustituido, (10) heterocicloalquilo, (11) heterocicloalquilo sustituido, (12) heterocicloalquilalquilo-, (13) heterocicloalquilalquilo- sustituido, (14) -C(O)R10 donde en un ejemplo R10 se selecciona del grupo que consiste en: alquilo, (15) arilheteroarilo-, (16) arilheteroarilo- sustituido, (17) heteroarilarilo-, tal como, por ejemplo, pirimidinilfenilo-, pirazinilfenilo-, piridinilfenilo-, furanilfenilo-, tienilfenilo-, y tiazolilfenilo-, (18) heteroarilarilo- sustituido, tal como, por ejemplo, pirimidinilfenilo- sustituido, sustituido pirazinilfenilo-, sustituido piridinilfenilo-, sustituido furanilfenilo-, sustituido tienilfenilo-, sustituido tiazolilfenilo-, y sustituido pirimidinilfenilo, (19) arilo, (20) arilo sustituido, (21) heteroarilo, (22) heteroarilo sustituido, (23) heteroarilheteroarilo-, (24) sustituido heteroarilheteroarilo-, (25) arilaminoheteroarilo-, (26) sustituido arilaminoheteroarilo-, (27) arilalquinilo-, (28) sustituido arilalquinilo-, (29) heteroarilalquinilo-, (30) sustituido heteroarilalquinilo-, (31) -C(O)NHR28, (32) cicloalquilheteroarilarilo-, (33) sustituido arilarilo-, (34) arilalquenilarilo-, (35) arilarilo-, (36) arilalquilo- sustituido, (37) arilalquilo-, (38) -SO2arilo, (39) benzoheteroaril-C(O)-(heterocicloalquilo sustituido)-, (40) heterocicloalquilo sustituido, (41) heterocicloalquil-C(O)-alquilo-, y (42) benzo[1,3]dioxolilo, donde dichos grupos R3, R4, R5, R6 y R7 sustituidos (7), (9), (11), (13), (16), (18), (20), (22), (24), (26), (28), (30), (33), (36), (39) y (40) estan sustituidos con 1 a 3 sustituyentes seleccionados independientemente del grupo que consiste en: -CH2OH, CN, -OH, -NH2, alquilo, alquenilo, halo, -C(O)-NH-R28, -C(O)NH2, -C(O)OR28, -C(O)R28, -C(alquil)=NOH, -C(alquil)=NO(alquilo), alcoxi, hidroxilo alquilo sustituido, dialquilamina donde cada grupo alquilo se selecciona independientemente, -CF3, -SO2alquilo, y -NHC(O)H, donde dichos grupos R3, R4, R5, R6 y R7 sustituidos (3) y (5) estan sustituidos con 1 a 3 sustituyentes seleccionados independientemente del grupo que consiste en: -NH2, halo, -C(O)-NH-R28, -C(O)OR28, y -C(O)R28; R8 se selecciona del grupo que consiste en: H, -OH, alquilo, arilo, -N(R10)2 y -NR10C(O)R12; cada R9 se selecciona independientemente del grupo que consiste en: halogeno, -CN, -NO2, -OR10, -SR10, -N(R10)2, y R10; cada R10 se selecciona independientemente del grupo que consiste en: H, alquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo, cicloalquilalquilo, heterocicloalquilo, heterocicloalquilalquilo, alquilheteroarilo-, alquilarilo-, alquilo sustituido, arilo sustituido, arilalquilo sustituido, heteroarilo sustituido, heteroarilalquilo sustituido, cicloalquilo sustituido, cicloalquilalquilo sustituido, heterocicloalquilo sustituido, heterocicloalquilalquilo sustituido, alquilheteroarilo- sustituido y alquilarilo- sustituido, y donde: dicho alquilo sustituido R10 esta sustituido con 1 a 3 sustituyentes seleccionados independientemente del grupo que consiste en: -NH2, -NHR20, -NO2, -CN, -OR26, halo, -C(O)-NH-R26, -C(O)OR26, y -C(O)R26, y dichos arilo sustituido, arilalquilo sustituido, heteroarilo sustituido, heteroarilalquilo sustituido, cicloalquilo sustituido, cicloalquilalquilo sustituido, heterocicloalquilo sustituido, heterocicloalquilalquilo sustituido, alquilheteroarilo- sustituido y alquilarilo- sustituido R10 estan sustituidos con 1 a 3 sustituyentes seleccionados independientemente del grupo que consiste en: (1) -NH2, (2) -NO2, (3) -CN, (4) -OH, (5) -OR20, (6) -OCF3, (7) -CF3, (8) -C(O)R38, (9) alquilo, (10) alquenilo, (11) halo, (12)-C(O)- NH-R26, (13) -C(O)OR38, (14) -C(O)-NR32-(C(R30)2)n- N(R38)2, (15) -S(O)tR38, (16) -C(O)-NR32-R38, (17) - NR32-C(O)-R38, **Fórmula** y (19) -NHR20; R11 se selecciona del grupo que consiste en: F, -OH, -CN, -OR10, -NHNR1R10, -SR10 y heteroarilo; R12 se selecciona del grupo que consiste en: alquilo, arilo, heteroarilo, cicloalquilo, cicloalquilalquilo, heterocicloalquilo y heterocicloalquilalquilo; R20 representa alquilo; R23 se selecciona del grupo que consiste en: H, alquilo, arilo, cicloalquilo, y cicloalquilalquil-; cada R26 se selecciona independientemente del grupo que consiste en: H y alquilo; R28 es alquilo; cada R30 se selecciona independientemente del grupo que consiste en: H, alquilo, y F; cada R32 se selecciona independientemente del grupo que consiste en: H y alquilo; cada R35 es H ; R36 se selecciona del grupo que consiste en: H y alquilo; cada R38 se selecciona independientemente del grupo que consiste en: H, alquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo, cicloalquilalquilo, heterocicloalquilo, heterocicloalquilalquilo, alquilheteroarilo-, alquilarilo-, alquilo sustituido, arilo sustituido, arilalquilo sustituido, heteroarilo sustituido, heteroarilalquilo sustituido, cicloalquilo sustituido, cicloalquilalquilo sustituido, heterocicloalquilo sustituido, heterocicloalquilalquilo sustituido, alquilheteroarilo- sustituido y alquilarilo- sustituido, y donde: dicho alquilo sustituido R38 esta sustituido con 1 a 3 sustituyentes seleccionados independientemente del grupo que consiste en: -NH2, -NO2, -CN, -OR26, halo, -C(O)-NH-R28, -C(O)OR28, y -C(O)R28, y dichos arilo sustituido, arilalquilo sustituido, heteroarilo sustituido, heteroarilalquilo sustituido, cicloalquilo sustituido, cicloalquilalquilo sustituido, heterocicloalquilo sustituido, heterocicloalquilalquilo sustituido, alquilheteroarilo- sustituido y alquilarilo- sustituido R38 estan sustituidos con 1 a 3 sustituyentes seleccionados independientemente del grupo que consiste en: (1) -NH2, (2) -NO2, (3) -CN, (4) -OH, (5) -OR20, (6) -OCF3, (7) -CF3, (8) -C(O)R26, (9) alquilo, (10) alquenilo, (11) halo, (12) -C(O)- NH-R26, (13) -C(O)OR26, (14) -C(O)-NR32-(C(R30)2)n- 30 N(R26)2, (15) -S(O)tR26, (16)-C(O)N(R32)(R26), (17) -NR32C(O)R26, (18) **Fórmula** y (19) -NHR20; R42 se selecciona del grupo que consiste en: alquilo, arilo, heteroarilo, y cicloalquilo; R44 se selecciona del grupo que consiste en: H, alquilo, cicloalquilo, y cicloalquilalquilo; y Cada R46 se selecciona independientemente del grupo que consiste en: H, alquilo, cicloalquilo, y cicloalquilalquilo; donde: cada alquilo incluyendo las porciones alquilicas de alquiloxi, arilalquilo, heteroarilalquilo, cicloalquilalquilo, heterocicloalquilalquilo, heterocicloalquil-C(O)-alquilo, alquilheteroarilo-, alquilarilo-, -C(alquil)=NOH, -C(alquil)=NO(alquilo), dialquilamina y -SO2alquilo significa un grupo hidrocarbonado alifatico que puede ser lineal o ramificado donde dicho grupo comprende de aproximadamente 1 a aproximadamente 20 atomos de carbono en la cadena; cada alcoxi o alquiloxi significa un grupo alquil-O-, es decir el enlace hacia el radical parental es a traves del ox
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77404306P | 2006-02-16 | 2006-02-16 | |
US774043P | 2006-02-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2353437T3 true ES2353437T3 (es) | 2011-03-02 |
Family
ID=38170991
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES07750497T Active ES2353437T3 (es) | 2006-02-16 | 2007-02-13 | Derivados de pirrolidina como inhibidores de erk. |
Country Status (17)
Country | Link |
---|---|
US (1) | US7807672B2 (es) |
EP (1) | EP1984331B1 (es) |
JP (1) | JP2009528280A (es) |
KR (1) | KR20080103996A (es) |
CN (1) | CN101415674A (es) |
AR (1) | AR059493A1 (es) |
AT (1) | ATE485268T1 (es) |
AU (1) | AU2007218059A1 (es) |
CA (1) | CA2642762A1 (es) |
DE (1) | DE602007009932D1 (es) |
ES (1) | ES2353437T3 (es) |
HK (1) | HK1117159A1 (es) |
IL (1) | IL193413A0 (es) |
MX (1) | MX2008010635A (es) |
TW (1) | TW200745089A (es) |
WO (1) | WO2007097937A1 (es) |
ZA (1) | ZA200807457B (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8546404B2 (en) | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
CA2706453A1 (en) * | 2007-11-30 | 2009-06-11 | Schering Corporation | Braf biomarkers |
RU2525389C2 (ru) * | 2008-02-21 | 2014-08-10 | Мерк Шарп И Доум Корп. | Соединения, которые являются ингибиторами erk |
DE102008022221A1 (de) | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
US9229008B2 (en) | 2008-08-19 | 2016-01-05 | Merck Sharp & Dohme Corp. | IL-8 level as a determinant of responsivity of a cancer to treatment |
EP2626072B1 (en) * | 2009-04-02 | 2019-12-04 | Merck Patent GmbH | Piperidine and piperazine derivatives as autotaxin inhibitors |
WO2011002067A1 (ja) * | 2009-07-02 | 2011-01-06 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
US8609675B2 (en) | 2009-07-02 | 2013-12-17 | Merck Sharp & Dohme Corp. | Fused Tricyclic Compounds as novel mTOR inhibitors |
WO2011041152A1 (en) | 2009-09-30 | 2011-04-07 | Schering Corporation | Novel compounds that are erk inhibitors |
CN104945382B (zh) * | 2009-10-14 | 2020-02-07 | 默沙东公司 | 提高p53活性的取代的哌啶和其用途 |
US8541404B2 (en) | 2009-11-09 | 2013-09-24 | Elexopharm Gmbh | Inhibitors of the human aldosterone synthase CYP11B2 |
US9062015B2 (en) | 2009-12-14 | 2015-06-23 | Merck Patent Gmbh | Inhibitors of sphingosine kinase |
CN101812007B (zh) * | 2010-04-27 | 2011-11-23 | 浙江大学 | 氨基吡咯类化合物及其制备方法 |
EP2608669B1 (en) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
CN103635472B (zh) | 2011-02-28 | 2018-01-12 | 阵列生物制药公司 | 丝氨酸/苏氨酸激酶抑制剂 |
CN103732592A (zh) | 2011-04-21 | 2014-04-16 | 默沙东公司 | 胰岛素样生长因子-1受体抑制剂 |
EP2736338B1 (en) | 2011-07-26 | 2019-01-23 | Merck Sharp & Dohme Corp. | FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS |
RU2014108140A (ru) | 2011-08-04 | 2015-09-10 | Эррэй Биофарма Инк. | Соединение на основе хинозолина в качестве ингибиторов серен-треониновых киназ |
GB201113538D0 (en) | 2011-08-04 | 2011-09-21 | Karobio Ab | Novel estrogen receptor ligands |
US8987274B2 (en) | 2011-10-28 | 2015-03-24 | Merck Sharp & Dohme Corp | Macrocycles that increase p53 activity and the uses thereof |
WO2013096150A1 (en) | 2011-12-21 | 2013-06-27 | Merck Sharp & Dohme Corp. | Substituted piperidines as hdm2 inhibitors |
WO2013109142A1 (en) | 2012-01-16 | 2013-07-25 | Stichting Het Nederlands Kanker Instituut | Combined pdk and mapk/erk pathway inhibition in neoplasia |
RS61500B1 (sr) | 2012-03-01 | 2021-03-31 | Array Biopharma Inc | Inhibitori serinske/treoninske kinaze |
MX369989B (es) | 2012-08-27 | 2019-11-27 | Array Biopharma Inc | Inhibidores de serina/treonina cinasa para el tratamiento de enfermedades hiperproliferativas. |
AU2013361694B2 (en) | 2012-12-20 | 2017-10-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as HDM2 inhibitors |
WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
WO2015041533A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | Rock in combination with mapk-pathway |
JP6427197B2 (ja) | 2013-10-03 | 2018-11-21 | クラ オンコロジー, インコーポレイテッド | Erkの阻害剤および使用方法 |
CN103922928A (zh) * | 2013-10-31 | 2014-07-16 | 北京利和知信科技有限公司 | 适用于制备烯烃聚合催化剂的环取代醚酸酯化合物 |
WO2015074081A1 (en) | 2013-11-18 | 2015-05-21 | Bair Kenneth W | Benzopiperazine compositions as bet bromodomain inhibitors |
BR122019007990B1 (pt) | 2013-11-18 | 2021-05-04 | Forma Therapeutics, Inc | Composto, e, composição farmacêutica |
WO2015156674A2 (en) | 2014-04-10 | 2015-10-15 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
WO2015178770A1 (en) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions for cancer treatment |
US10864179B2 (en) | 2015-10-01 | 2020-12-15 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma |
WO2017099591A1 (en) | 2015-12-07 | 2017-06-15 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Treatment of inhibitor resistant braf-mutant cancers |
WO2017204626A1 (en) | 2016-05-24 | 2017-11-30 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Combination therapy - combined map2k4/map3k1 and mek/erk inhibition |
CN111646979B (zh) * | 2018-01-23 | 2021-08-31 | 深圳市塔吉瑞生物医药有限公司 | 取代的哒嗪酮化合物 |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2306108A (en) | 1995-10-13 | 1997-04-30 | Merck & Co Inc | Treatment of Raf-mediated cancers with imidazole derivatives |
AU3215197A (en) | 1996-05-30 | 1998-01-05 | Merck & Co., Inc. | A method of treating cancer |
GB2323845A (en) | 1997-03-31 | 1998-10-07 | Merck & Co Inc | MEK inhibiting lactones |
JP2001510168A (ja) | 1997-07-18 | 2001-07-31 | ノボ ノルディスク アクティーゼルスカブ | FVIIa媒介性細胞内シグナル伝達経路に関連する反対条件の処理のためのFVIIa又はFVIIaiの使用 |
GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
JP4783532B2 (ja) | 2000-02-05 | 2011-09-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | Erkのインヒビターとして有用なピラゾール組成物 |
EP1207864A2 (en) | 2000-02-05 | 2002-05-29 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of erk |
JP2003527379A (ja) | 2000-03-15 | 2003-09-16 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | Mex阻害物質としての5−アミド置換ジアリールアミン類 |
TWI310684B (en) | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
US7211594B2 (en) * | 2000-07-31 | 2007-05-01 | Signal Pharmaceuticals, Llc | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith |
US20050009876A1 (en) * | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
ZA200301696B (en) | 2000-09-15 | 2004-04-28 | Vertex Pharma | Isoxazoles and their use as inhibitors of erk. |
MXPA03002294A (es) | 2000-09-15 | 2005-09-08 | Vertex Pharma | Compuestos de pirazol utiles como inhibidores de proteina cinasa. |
EP1345922B1 (en) * | 2000-12-21 | 2006-05-31 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
US6982274B2 (en) * | 2001-04-16 | 2006-01-03 | Eisai Co., Ltd. | 1H-indazole compound |
US6706711B2 (en) | 2001-04-27 | 2004-03-16 | Vertex Pharmaceuticals Incorporated | Pyrazole derived kinase inhibitor |
MXPA03009846A (es) | 2001-04-27 | 2004-05-05 | Vertex Pharma | Derivados de triazol inhibidores de cinasa y usos de los mismos. |
US6750239B2 (en) | 2001-08-03 | 2004-06-15 | Vertex Pharmaceuticals Incorporated | Pyrazole-derived kinase inhibitors and uses thereof |
MXPA04001088A (es) | 2001-08-03 | 2004-05-20 | Vertex Pharma | Derivados de pirazol como inhibidores de cinasa y uso de los mismos. |
EP1438295B1 (en) | 2001-10-23 | 2012-08-15 | Merck Serono SA | Azole derivatives and pharmaceutical compositions containing them |
US20030187026A1 (en) * | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
AU2003237121A1 (en) * | 2002-04-26 | 2003-11-10 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
AU2003233605A1 (en) | 2002-05-24 | 2003-12-12 | The University Of Utah Research Foundation | Mitogen activated protein kinase inhibitor compositions for lymphoma therapy |
IL164209A0 (en) * | 2002-05-31 | 2005-12-18 | Eisai Co Ltd | Pyrazole derivatives and pharmaceutical compositions containing the same |
US7196092B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corporation | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US7205308B2 (en) | 2002-09-04 | 2007-04-17 | Schering Corporation | Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors |
EP1539756B1 (en) | 2002-09-19 | 2007-11-14 | Schering Corporation | Imidazopyridines as cyclin dependent kinase inhibitors |
DE602004024374D1 (de) | 2003-03-13 | 2010-01-14 | Vertex Pharma | Zusammensetzungen zur verwendung als protein-kinase-inhibitoren |
WO2005002673A1 (en) | 2003-07-03 | 2005-01-13 | Astex Therapeutics Limited | Raf kinase inhibitors |
JP2007521331A (ja) * | 2003-11-19 | 2007-08-02 | シグナル ファーマシューティカルズ,エルエルシー | 複数キナーゼの標的化による疾患及び障害の治療方法 |
EP1715871A1 (en) | 2003-12-22 | 2006-11-02 | Gilead Sciences, Inc. | Kinase inhibitor phosphonate conjugates |
JP2007530595A (ja) * | 2004-03-26 | 2007-11-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | Erk2のピリジンインヒビターおよびそれらの使用 |
JP2007532615A (ja) | 2004-04-13 | 2007-11-15 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
EP3305776B1 (en) * | 2004-05-14 | 2019-09-25 | Vertex Pharmaceuticals Incorporated | Pyrrole compounds as inhibitors of erk protein kinases and pharmaceutical compositions containing these compounds |
AU2005245877B2 (en) | 2004-05-14 | 2010-06-03 | Vertex Pharmaceuticals, Incorporated | Prodrugs of pyrrolylpyrimidine ERK protein kinase inhibitors |
WO2006040569A1 (en) | 2004-10-14 | 2006-04-20 | Astex Therapeutics Limited | Thiophene amide compounds for use in the treatment or prophylaxis of cancers |
US7501415B2 (en) | 2004-12-23 | 2009-03-10 | Vertex Pharmaceuticals Incorporated | Selective inhibitors of ERK protein kinase and uses thereof |
CN100377868C (zh) * | 2005-03-24 | 2008-04-02 | 中国科学院物理研究所 | 用于磁性/非磁性/磁性多层薄膜的核心复合膜及其用途 |
WO2006136008A1 (en) | 2005-05-24 | 2006-12-28 | University Health Network | Salicylic acid hydrazones as inhibitors of the erk mapkinase pathway and for the treatment of cancer |
US8217042B2 (en) * | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
US8546404B2 (en) * | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
NZ569087A (en) * | 2005-12-13 | 2011-09-30 | Schering Corp | Polycyclic indazole derivatives that are ERK inhibitors |
EP2018872A4 (en) * | 2006-04-20 | 2010-06-09 | Takeda Pharmaceutical | PHARMACEUTICAL PRODUCT |
US7601852B2 (en) * | 2006-05-11 | 2009-10-13 | Kosan Biosciences Incorporated | Macrocyclic kinase inhibitors |
BRPI0713119A2 (pt) * | 2006-06-30 | 2012-04-17 | Schering Corp | piperidinas substituìdas que aumentam a atividade de p53 e os usos destas |
US7671832B2 (en) * | 2006-07-10 | 2010-03-02 | Philips Lumileds Lighting Company, Llc | Multi-colored LED backlight with color-compensated clusters near edge |
EP2548558A1 (en) | 2007-03-28 | 2013-01-23 | Pharmacyclics, Inc. | Nitrogen-containing condensed heterocyclic as inhibitors of bruton's tyrosine kinase |
CN101790526A (zh) | 2007-06-08 | 2010-07-28 | 雅培制药有限公司 | 用作激酶抑制剂的5-杂芳基取代的吲唑化合物 |
CN101772501A (zh) | 2007-06-18 | 2010-07-07 | 先灵公司 | 杂环化合物及其作为erk抑制剂的用途 |
RU2525389C2 (ru) | 2008-02-21 | 2014-08-10 | Мерк Шарп И Доум Корп. | Соединения, которые являются ингибиторами erk |
-
2007
- 2007-02-13 KR KR1020087022312A patent/KR20080103996A/ko not_active Application Discontinuation
- 2007-02-13 AT AT07750497T patent/ATE485268T1/de not_active IP Right Cessation
- 2007-02-13 DE DE602007009932T patent/DE602007009932D1/de active Active
- 2007-02-13 ES ES07750497T patent/ES2353437T3/es active Active
- 2007-02-13 CA CA002642762A patent/CA2642762A1/en not_active Abandoned
- 2007-02-13 AU AU2007218059A patent/AU2007218059A1/en not_active Abandoned
- 2007-02-13 EP EP07750497A patent/EP1984331B1/en active Active
- 2007-02-13 JP JP2008555293A patent/JP2009528280A/ja not_active Withdrawn
- 2007-02-13 WO PCT/US2007/003665 patent/WO2007097937A1/en active Application Filing
- 2007-02-13 MX MX2008010635A patent/MX2008010635A/es unknown
- 2007-02-13 CN CNA2007800113120A patent/CN101415674A/zh active Pending
- 2007-02-13 US US11/705,709 patent/US7807672B2/en not_active Expired - Fee Related
- 2007-02-14 AR ARP070100620A patent/AR059493A1/es unknown
- 2007-02-15 TW TW096105603A patent/TW200745089A/zh unknown
-
2008
- 2008-08-12 IL IL193413A patent/IL193413A0/en unknown
- 2008-08-29 ZA ZA200807457A patent/ZA200807457B/xx unknown
- 2008-11-03 HK HK08112047.0A patent/HK1117159A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
TW200745089A (en) | 2007-12-16 |
IL193413A0 (en) | 2009-05-04 |
US7807672B2 (en) | 2010-10-05 |
JP2009528280A (ja) | 2009-08-06 |
CN101415674A (zh) | 2009-04-22 |
CA2642762A1 (en) | 2007-08-30 |
EP1984331A1 (en) | 2008-10-29 |
DE602007009932D1 (de) | 2010-12-02 |
ZA200807457B (en) | 2009-09-30 |
AU2007218059A1 (en) | 2007-08-30 |
ATE485268T1 (de) | 2010-11-15 |
WO2007097937A1 (en) | 2007-08-30 |
US20070232610A1 (en) | 2007-10-04 |
AR059493A1 (es) | 2008-04-09 |
HK1117159A1 (en) | 2009-01-09 |
KR20080103996A (ko) | 2008-11-28 |
MX2008010635A (es) | 2008-10-28 |
EP1984331B1 (en) | 2010-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2353437T3 (es) | Derivados de pirrolidina como inhibidores de erk. | |
AR068046A1 (es) | Derivados policiclicos de indazol y su uso como inhibidores de erk para el tratamiento del cancer | |
AR056891A1 (es) | Derivados policiclicos de indazol que son inhibidores de erk | |
AR061847A1 (es) | Derivados de pirimidina 2- amino -5- sustituida. como inhibidores de quinasas. composiciones farmaceuticas. | |
AR109424A2 (es) | Pirimidil ciclopentanos hidroxilados y metoxilados como inhibidores de la proteína quinasa akt | |
PE20070808A1 (es) | COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA | |
PE20071286A1 (es) | Composicion para inducir tolerancia viral en plantas | |
CO6180439A2 (es) | Derivados de quinuclidinol como antagonistas de receptores muscarinicos | |
AR049125A1 (es) | Heterociclos biciclicos nitrogenados inhibidores de la aromatasa. | |
AR050181A1 (es) | Derivados de urea ciclicos sustituidos, su preparacion y su uso farmaceutico como inhibidores de quinasa | |
TNSN06019A1 (en) | Pharmaceutical compounds | |
CO6190515A2 (es) | Derivados indolicos con anilo unido en las posiciones 4,5 y sus metodos de uso | |
UY31750A (es) | Compuestos y composiciones como inhibidores de quinasa | |
AR023703A1 (es) | N-carboniloximetilesteres de nitroetilendiaminas y nitroguanidinas, proceso para su preparacion, composicion parasiticida, una preparacion en combinacionpara controlar parasitos en animales de sangre caliente, uso de dichos compuestos y compuestos intermediarios para su uso en dicho proceso de prepa | |
BRPI0519288A2 (pt) | compostos heterocÍclicos como antagonistas de ccr2b | |
AR055053A1 (es) | Compuestos indol sustituidos con actividad inhibidora de nos. composiciones farmaceuticas. | |
CO5630023A2 (es) | Fenil quinolinas y su uso como agentes estrogenicos | |
CO6150144A2 (es) | Inhibidores de proteina tirosina fosfatasa humana y metodos de uso | |
AR071739A1 (es) | Inhibidores de transcriptasa reversa | |
AR060050A1 (es) | Compuestos moduladores del receptor de s1p y uso de los mismos | |
NI201000011A (es) | Derivados de pirimidina 934. | |
PE20090216A1 (es) | Compuestos triazolil aminopirimidina | |
CO6020016A1 (es) | Derivados de 1,2,4,5 tetrahidro-3h-benzapezinas su procedimiento de preparacion y las composiciones farmaceuticas que las contienen | |
CO5690593A2 (es) | Nuevos derivados de pirimidin 2-amina | |
CO6150147A2 (es) | Derivados de 5,6-bisaril-2-piridin-carboxamida su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii |